Median Technologies announced that it has received a €19 million payment under the first tranche of its new financing agreement with the European Investment Bank (EIB), executed July 11, 2025 and representing the initial drawdown of a facility totaling up to €37.5 million.
The funding will support Median’s commercial launch of its eyonis LCS software-as-a-medical-device (SaMD) for lung cancer screening in the U.S. and Europe, and accelerate expansion of the broader eyonis suite across other oncology indications. Concurrently, Median completed the repayment of €20.7 million on October 17 2025, representing the first tranche of its 2019 EIB loan facility.
Following these transactions, the company’s cash runway is extended through Q4 2026. The August capital increase of €23.9 million, combined with the financing agreement and potential exercise of warrants, could generate up to an additional €51.7 million in cash.
The loan agreement is structured in three tranches: Tranche A of €19 million (received), Tranche B of €8.5 million and Tranche C of €10 million, each subject to certain performance, equity financing and warrant issuance conditions. Tranche A bears a 5% interest rate, carries a six-year maturity and includes a three-year grace period. Simultaneously, Median issued 3,403,164 warrants at an exercise price of €2.764, with a 30-year maturity.
Median noted that these funds strengthen its financial position ahead of anticipated U.S. 510(k) clearance and CE-marking for eyonis LCS slated for Q1 2026, positioning the company for commercialization in its key markets.
KEY QUOTE:
“We have been collaborating with the European Investment Bank since 2019, and this long-standing partnership is continuing to deliver tangible results. The disbursement of the first €19 million tranche under the 2025 EIB financing facility will further accelerate the commercial launch and sales ramp-up of eyonis LCS, our AI-powered Software as a Medical Device for lung cancer screening, in both the U.S. and Europe and support the expansion of our eyonis suite towards other cancer indications. We have also proceeded with repayment of the first tranche of our 2019 loan from the EIB, which was undertaken on October 17, 2025.”
Fredrik Brag, CEO and Founder, Median Technologies
